[Vedolizumab (Entyvio®) for the treatment of inflammatory bowel diseases].

@article{Kemseke2015VedolizumabF,
  title={[Vedolizumab (Entyvio®) for the treatment of inflammatory bowel diseases].},
  author={Catherine Van Kemseke and Edouard V Louis and Cath{\'e}rine Reenaers},
  journal={Revue medicale de Liege},
  year={2015},
  volume={70 11},
  pages={575-82}
}
Anti-TNF agents are highly effective in treating inflammatory bowel diseases, but loss of response and side-effects leading to drug interruption are often reported. New molecules are needed to treat these patients. Vedolizumab is a fully humanized anti-body inhibiting the migration of circulating lymphocytes to the gut by binding the integrin α4β7. In… CONTINUE READING